There are currently no events to display.

Recent News

Date Title and Summary
Toggle Summary ViewRay Launches Clinical Trial Following Compelling Early Pancreatic Cancer Data with MRIdian System
First Initiative Based on Retrospective Study That Suggests Potential for Significantly Prolonged Survival CLEVELAND , Sept. 25, 2017 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today the launch of a multi-center prospective clinical trial for locally advanced unresectable pancreatic
Toggle Summary ViewRay MRIdian to be Featured in 21 Presentations from Seven Leading Centers at ASTRO
ViewRay to Host Inaugural Clinical Cooperative Think Tank Meeting to Advance MR-Guided Radiation Therapy Research CLEVELAND , Sept. 21, 2017 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian and MRIdian Linac systems will be featured at the Annual Meeting of
Toggle Summary ViewRay® to Host Analyst & Investor Meeting at ASTRO in San Diego
CLEVELAND , Sept. 20, 2017 /PRNewswire/ --  ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will hold a meeting for analysts and investors on Monday, September 25, 2017 , during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego .
Toggle Summary ViewRay® to Participate in Morgan Stanley Global Healthcare Conference
CLEVELAND , Sept. 6, 2017 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York, NY .

Corporate Profile

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first and only MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian® addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian®’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian® will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Featured Items

Upcoming Events

There are currently no events to display.

Stock Quote

Event Calendar more >

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

Click here for E-mail Alerts

Copyright Nasdaq. Minimum 15 minutes delayed.

Copyright 2017 © ViewRay. All rights reserved